Transcript Luca Pani - European Medicines Agency

Curriculum vitae
PERSONAL INFORMATION
Luca Pani
WORK EXPERIENCE
January 2013–Present
Member
EMA (United Kingdom)
Member of the European Risk Management Strategy Facilitation Group (ERMS-FG)
November 2013–Present
Chair<p>Chair of the European Union Management Board Telematic Committee
(EUMBTC) </p
EMA (United Kingdom)
Chair of the European Union Management Board Telematic Committee (EUMBTC)
November 2011–Present
Director General
Italian Medicines Agency (AIFA) (Italy)
Director General of the Italian Medicines Agency (AIFA)
January 2012–Present
Member
EMA (United Kingdom)
Member of the Management Board Telematics Committee (MBTC) of the European Medicine Agency
(EMA)
January 2011–Present
Management Board EMA Member
EMA (United Kingdom)
Management Board EMA Member
January 2011–Present
Voluntary Professor
University of Miami– M. Miller School of Medicine (Department of Psychiatry & Behavioral Sciences)
(United States)
Voluntary Professor of the University of Miami– M. Miller School of Medicine (Department of
Psychiatry & Behavioral Sciences)
January 2010–Present
Italian Permanent Member, Committee for Human Medicine Products (CHMP)
EMA (United Kingdom)
Italian Permanent Member, Committee for Human Medicine Products (CHMP),
European Medicines Agency (EMA)
January 2010–Present
Member of theWorking Party on Central Nervous System (WP-CNS)
EMA (United Kingdom)
Member of theWorking Party on Central Nervous System (WP-CNS), European
Medicines Agency (EMA
January 2010–Present
Member of the Scientific Advice Working Party (SA-WP)
EMA (United Kingdom)
Member of the Scientific Advice Working Party (SA-WP), European Medicines Agency (EMA)
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 1 / 27
Curriculum vitae
January 2009–December 2011
Luca Pani
Member Committee for Clinical Neurosciences
AIFA (Italy)
Member, Committee for Clinical Neurosciences, Italian Medicines Agency (AIFA)
January 2009–December 2011
Head of the National Research Council’s Institute of Translationalpharmacology
CNR (Italy)
Headof Research of the National Research Council’s Institute of Translationalpharmacology (CNR –
ITP), located in Pula-Cagliari
January 2008–December 2010
Consultant
Media Ltd Consultant (United Kingdom)
3PS Media Ltd Consultant
January 2008–December 2011
Founder and Permanent Member of the Scientific Board of Fase 1
Regione Autonoma della Sardegna (Italy)
Founder and Permanent Member of the Scientific Board of Fase 1, the first Government based
(Regione Autonoma della Sardegna) Contract Research Organization dedicated to Fase 1 studies in
Translational Pharmacology
January 2006–December 2010
Head Section of Neuropharmacology Pula-Cagliari
Milano Italian National Research Council (Italy)
Head Section of Neuropharmacology Pula-Cagliari, Institute of Biomedical Technologies, Milano
Italian National Research Council
January 2002–October 2016
Director of Research
Italian National Research Council (Italy)
Director of Research, Italian National Research Council. Cagliari
January 2002–December 2010
President
Pharmaness Neuroscienze (Italy)
President, Pharmaness Neuroscienze(Board of Directors member – Resignation: August 5th, 2010)
January 2004–December 2009
President
Proteios Srl (Italy)
President, Proteios Srl (closed)
January 2005–December 2008
President
ProKemia Consorzio Regione Autonoma Sardegna (United Kingdom)
President ProKemia Consorzio (closed)
January 2001–December 2001
Senior Researcher
Institute of Neurogenetic and Neuropharmacology. National Research Council, (Italy)
Senior Researcher Institute of Neurogenetic and Neuropharmacology. National Research Council,
Cagliari
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 2 / 27
Curriculum vitae
January 1999–December 2002
Luca Pani
CEO
Pharmaness Neuroscienze (Italy)
CEO, Pharmaness Neuroscienze
January 1992–December 1993
Research Assistant Professor
Fidia Georgetown Institute for the Neurosciences and Department of Pharmacology, Georgetown
University School of Medicine (United States)
Research Assistant Professor Fidia Georgetown Institute for the Neurosciences and Department of
Pharmacology, Georgetown University School of Medicine. Washington, D.C.
January 1990–December 1992
Research Associate
University of Illinois (United States)
Research Associate. Dept. of Biochemistry University of Illinois at Chicago
January 1988–December 1989
Medical Assistant
Psychiatric Hospital “Villa Clara” (Italy)
Medical Assistant (tenured). Psychiatric Hospital “Villa Clara”. Cagliari
January 1985–December 1988
Resident in Psychiatry
Centro Lucio Bini (Italy)
Resident in Psychiatry, Centro Lucio Bini, Prof. Athanasio Koukopoulos Mentor and Clincal
Supervisor, Rome
November 2015–October 2016
Member of the Management Group HMA
HMA (United Kingdom)
EDUCATION AND TRAINING
September 1992–June 1994
Assistant Professor
Georgetown University (United States)
Assistant Professor in Molecular Biology and Pharmacology
January 1990–December 1991
Post Doctoral
University of Illinois (United States)
Post Doctoral Fellowship in Molecular Biology
January 1985–December 1989
Specialty in Psychiatry
University of Naples (Italy)
Specialty in Psychiatry
January 1986–December 1988
Medical Officer
Italian Navy Head of South Sardinia Command General Medicine Headquarters (Italy)
September 1979–June 1985
Medical Degree
University of Cagliari (Italy)
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 3 / 27
Curriculum vitae
Luca Pani
ADDITIONAL INFORMATION
Expertise
Luca Pani from 2002 to 2010 has been the President of PharmaNess Scarl (PharmaNess) one of the
most important European non-profit Research Centres focusing on pharmacology and biotechnology
(see www.pharmaness.it). PharmaNess’ shareholders are currently fully private (100%), while until
2010 when he was President the University of Cagliari (16.4% www.unica.it) and the National
Research Council of Italy (8.6% circa www.cnr.it), held part of the shares. PharmaNess held a leader
position in the Biomedicine District of Sardinia and it worked in close collaboration with prestigious
Universities, research institutes and private organizations located in Italy and in other countries.
2007 -2010 Luca Pani entered a partnership with John Fairbairn and Bruno Kavanaugh (www.casebuilder.com) for the highest level of medical education and information dissemination in the field of
Mental Disorders.
1990-1991 Fidia Research Foundation International Fellowship in Neuroscience.
Platano d’Oro: Italian National Medical Writing Prize, Finalist in all the first three editions of the prize
(1994-1996-1998).
Luca Pani contributes regularly to the Science Almanac of the Italian Research Council
(www.almanacco.rm.cnr.it) the largest Italian Research Institution.
Luca Pani is (or has been) a member of the Italian Society of Pharmacology; Italian Society of
Psychopathology; Italian Society of Psychiatry; Italian Society for Psychoneuropharmacology.
National Expert with the task force on Bionanotechnology of the National Committee on Biosecurity
and Biotechnology for the Prime Minister Counsel (Presidenza del Consiglio dei Ministri) (see
www.governo.it/biotecnologie/documenti/Bionanotecnologie.pdf)
On Jan, 20th 2009 Luca Pani was appointed as Scientific Advisor in the Psychotic Disorders and
Antipsychotic Panel of the European College of Neuropsychopharmacology (ECNP). ECNP was
founded in 1987, is currently the largest platform of European Neuropsychopharmacologists and has
now more than 900 members.
Luca Pani has founded, launched and co-directed (1993-2003) with PP Pani and GL Gessa, The
Italian Journal of the Addictions (www.medicinatossicodipendenze.it) and has selected, judged and
edited the articles of the Journal over a decade.
Luca Pani is on the Editorial Board of Clinical Neuropsychiatry (www.clinicalneuropsychiatry.org); the
Italian Journal of Psychiatry and Psychotherapy, and the Italian Edition of the American Journal of
Psychiatry (www.arsxxi.it/AJP)
Committee Member for the career advancement of the highest position of Director of Research of the
National Research Council of Italy (www.cnr.it), the largest and most important research institution in
the Country.
For the period 2007-2010 Luca Pani has been appointed by the Italian Research Council as Deputy
Representative in the International Committee on Laboratory Animal Science (ICLAS)
Since 2007 Luca Pani has been appointed in the Scientific Board of Directors of Fase Uno
www.sardegnaricerche.it/fase1/ the first Government based Contract Research Organization
dedicated to early stage Clinical Trials in Drug Discovery. In 2011 he resigned.
Since 2009, Member on the Technical Committee for Clinical Neurosciences at the AIFA (The Italian
equivalent of the Federal Drug Agency).
2009-2014 Member on the Technical Committee for Pharmaceutical Support of the Regione
Autonoma della Sardegna.
Publications
1) Serra G; Collu M; D'Aquila P; Pani L; Gessa G
Are D1 DA receptors agonist potential antidepressant?
Pharmacol. Res. Comm. 1988 20 12 1121 1123
2) Rossetti ZL; Pani L; Gessa GL.
Differential postmortem release of noradrenaline and dopamine from rat brain.
Psychopharmacology (Berlin) 1989; 98 (4): 562 563
3) Rossetti ZL; Pani L; Portas C; Gessa GL.
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 4 / 27
Curriculum vitae
Luca Pani
Brain dialysis provides evidence for D2 dopamine receptors modulating
noradrenaline release in the rat frontal cortex.
Eur J Pharmacol 1989 Apr 25; 163(2 3): 393 395
4) Rossetti ZL; Portas C; Pani L; Carboni S; Gessa GL.
Stress increases noradrenaline release in the rat frontal
cortex: prevention by diazepam.
Eur J Pharmacol 1990 Feb 6;176(2):229 31
5) Pani L; Carboni S; Kusmin A; Gessa GL; Rossetti ZL.
Nimodipine inhibits cocaine induced dopamine release and motor stimulation.
Eur J Pharmacol 1990 Feb 6;176(2):245 246
6) Pani L; Gessa GL; Carboni S; Portas CM; Rossetti ZL.
Brain dialysis and dopamine: does the extracellular concentration
of dopamine reflect synaptic release?
Eur J Pharmacol 1990 May 3;180(1):85 90
7) Carboni S; Melis F; Pani L; Hadjiconstantinou M; Rossetti ZL .
The non competitive NMDA receptor antagonist MK 801 prevents the massive release
of glutamate and aspartate from rat striatum induced by l methyl 4 phenylpyridinium (MPP+).
Neurosci Lett 1990 Sep 4;117(1 2):129 133
8) Rossetti ZL; Pani L; Kuzmin A; Carboni S; Gessa GL.
Dihydropyridine calcium antagonists prevent cocaine , but not amphetamine ,
induced dopamine release and motor activity in rats.
Acta Physiol Hung 1990;75 Suppl:249 250
9) Pani L; Kuzmin A; Stefanini E; Gessa GL; Rossetti ZL.
Flunarizine potentiates cocaine induced dopamine release and motor stimulation in rats.
Eur J Pharmacol 1990 Nov 6;190(1 2):223 227
10) Pani L; Kuzmin A; Diana M; De Montis G ; Gessa GL ; Rossetti ZL.
Calcium receptor antagonists modify cocaine effects in the central nervous system differently.
Eur J Pharmacol 1990 Nov 6;190(1 2):217 221
11) Pani L; Kuzmin A; Martellotta MC; Gessa GL; Fratta W.
The calcium antagonist PN 200 110 inhibits the reinforcing properties of cocaine.
Brain Res Bull 1991 Mar;26(3):445 447
12) Devoto P; Pani L; Kuzmin A; De Montis G.
Inhibition of 3H dopamine uptake by Flunarizine
Eur. J. Pharmacol. 1991 203 , 67 70
13) Diana M; Pani L; Rossetti Z; Passino N; Gessa G.L.
Flunarizine attenuates cocaine induced inhibition of A9 dopaminergic neurons.
Pharmacol. Res. 1991, 24, 197 203
14) Pani L., Kuzmin A., Diana M., De Montis G., Gessa G.L., Rossetti Z.
Dihydropyridine calcium antagonists prevent cocaine-induced dopamine release
and motor activity in rats
Posters in Neuroscience, 1991, 1, 85-88
15) Pani L; Clevidence D; Qian X ; Costa R.H.
The restricted promoter activity of the liver transcription factor Hepatocyte Nuclear
Factor 3 involves a cell specific factor and positive autoactivation.
Molecular and Cell Biology1992 , XII, 552 562
16) Pani L; Overdier D.G; Porcella A; Qian X; Lai E; Costa R.H.
Hepatocyte Nuclear Factor 3ß contains two transcriptional activation domains, one of which is novel
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 5 / 27
Curriculum vitae
Luca Pani
and conserved with the Drosophila Fork Head protein.
Molecular and Cell Biology 1992 , XII, 3723-3732.
17) Clevidence D.E; Overdier D.G; Tao W; Qian X; Pani L; Lai E; Costa R.H.
Identification of Nine Novel Tissue-Specific Transcription factors of the Hepatocyte nuclear factor 3 /
Forkhead DNA-Binding-Domain Family.
P.N.A.S. 1993, 90, 3948-3952.
18) Cavallaro S.; Pani L.; Guidotti A.; Costa E.
ACTH induced mitochondrial DBI receptor (MDR) and diazepam binding inhibitor (DBI) expression in
adrenal of hypophysectomized rat in not cause-effect relatedto its immediate steroidogenic action.
Life Sciences 1993, 53:1137-1147.
19) Kolmer M; Alho H; Costa E; Pani L.
Cloning and tissue specific functional characterization of the rat Diazepam Binding Inhibitor promoter.
P.N.A.S. 1993, Vol. 90, 8439-8443.
20) D’Aquila PS; Collu M; Pani L; Gessa GL ; Serra G.
Antidepressant-like effect of selective D1 receptors agonist in the behavioural despair animal model of
depression.
Eur. J. Pharmacol. 1994, 262, 107-111
21) Fadda P., Pani L., Porcella A., Fratta W.
Chronic imipramine, L-Sulpiride and mianserin decrease corticotropin releasing factor levels in the rat
brain.
Neurosci. Letters 1995, 192, 121-123
22) Gessa GL, Pani L., Fadda P., Fratta W.
Sleep deprivation in the rat: an animal model of mania.
Eur. Neuropsychopharmacology Suppl., 1995, 89-93
23) Samadani U., Porcella A., Pani L., Johnson P.F. Burch J., Pine R., Costa R.H.
Cytokine Regulation of the Liver Transcription Factor HNF-3ß is mediated by the C/EBP
Family and Interferon Regulatory Factor 1.
Cell Growth & Differentiation, 1995, 6, 879-890
24) Koukopoulos A., Pani L., Serra G., Minnai G., Reginaldi D.
La dépression anxieuse-excitée: un syndrome affectif mixte
L’Encéphale, 1995 ; VI Sp, 33-36
25) Colangelo A.M.; Pani L., Mocchetti I.
Correlation between increased AP-1 NGF binding activity and induction of nerve growth factor
transcription expression by multiple signal transduction in C6-2B glioma cells
Molecular Brain Research, 1996, 35, 1-10
26) Akiskal HS. Bolis CL. Cazzullo C. Costa e Silva JA. Gentil V. Lecrubier Y. Licinio J. Linden M.
Lopez-Ibor JJ. Ndiaye IP. Pani L. Prilipko L. Robertson MM. Robinson RG. Starkstein SE. Thomas P.
Wang Y. Wong ML., Dysthymia in neurological disorders.
Molecular Psychiatry., 1996, 1:478-491
27) Galli R. Michelini S. Bartalena L. Massetani R. Pani L. Grasso L. Cassano GB. Martino E. Purdy
RH. Murri L.,
Circulating levels of anticonvulsant metabolites of progesterone in women with partial epilepsy in the
intercritical phase.
Italian Journal of Neurological Sciences, 1996, 17:277-281,
28) Collu M. Poggiu AS. Pani L. Serra G.,
Fluoxetine-induced conditioned place preference: a preliminary study,
Synapse., 1997, 25:309-311.
29) Murru S. Pani L. Poddie D. Gessa G. Cao A. Pirastu M.
Rat tyrosine hydroxylase gene polymorphisms.
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 6 / 27
Curriculum vitae
Luca Pani
Molecular Brain Research., 1997, 45:345-348
30) Pani L. Gessa GL.
Evolution of the dopaminergic system and its relationships with the psychopathology of pleasure.
International Journal of Clinical Pharmacology Research., 1997, 17:55-58.
31) Pani L. Gessa GL.
The role of dopamine in the biological basis of dysthymia.
Italian Journal of Psychiatry and Behavioural Sciences, 1998, 8:5-9
32) Porcella A. Gessa GL. Pani L.
Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related
antigens in the rat brain.
European Journal of Neuroscience., 1998 10:1743-1751.
33) Porcella A. Casellas P. Gessa GL. Pani L.
Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the
antiglaucoma properties of marihuana.
Molecular Brain Research, 1998, 58:240-245.
34) Pani L. Porcella A. Gessa GL.,
The role of stress in the pathophysiology of the dopaminergic system.
Molecular Psychiatry, 2000, 5:14-21
35) Porcella A. Maxia C. Gessa GL. Pani L.
The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein.
European Journal of Neuroscience, 2000, 12:1123-1127
36) Pani L.
Is there an evolutionary mismatch between the normal physiology of the human dopaminergic system
and current environmental conditions in industrialized countries?
Molecular Psychiatry, 2000, 5:467-475
37) Ruiu S. Marchese G. Saba PL. Gessa GL. Pani L.
The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex
Molecular Psychiatry, 2000, 5:673-677
38) Porcella A. Maxia C. Gessa GL. Pani L.
The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma
resistant to conventional therapies.
European Journal of Neuroscience, 2001, 13:409-412
39) Saba L. Porcella A. Congeddu E. Colombo G. Gessa GL. Peis M. Pistis M. Pani L.
The R100Q mutation of the GABAA 6 receptor subunit may contribute to voluntary aversion to
ethanol in the sNP rat line
Molecular Brain Research, 2001, 87:263-270
40) Devoto P. Flore G. Ibba A. Fratta W Pani L.
Lead intoxication during intrauterine life and lactation but not during adulthood reduces nucleus
accumbens dopamine release as studies by brain microdialysis.
Toxicology Letters, 2001, 121:199-206.
41) Devoto P. Flore G. Pani L. Gessa G. L.
Evidence for co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral
cortex
Molecular Psychiatry, 2001, 6:657-664
42) Castelli MP, Mocci I, Sanna AM, Gessa GL, Pani L
S(-) Amisulpride binds with high affinity to cloned dopamine D2 and D3 receptors
European Journal of Pharmacology, 2001, 432: 143-147
43) Pani L., Gessa G.L.
The substituted benzamides and their clinical potential on dysthymia and on the negative
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 7 / 27
Curriculum vitae
Luca Pani
symptoms of schizophrenia
Molecular Psychiatry, 2002, 7:247-253
44) Casu MA, Colombo G, Gessa GL, Pani L.
Reduced TH-immunoreactive fibers in the limbic system of Sardinian alcohol-preferring rats
Brain Research, 2002, 924:242-251
45) Marchese G, Casu MA, Bartholini F, Ruiu S, Saba PL, Gessa GL, Pani L.
Sub-chronic treatment with classical but not atypical antipsychotics produces morphological changes
in rat nigro-striatal dopaminergic neurons directly related to `early onset' vacuous chewing
European Journal of Neuroscience, 2002, 15:1-11
46) Marchese G, Bartholini F, Ruiu S, Casti P, Saba PL, Gessa GL, Pani L.
Effect of amisulpride isomers on rat catalepsy
European Journal of Pharmacology, 2002 444:69-76.
47) Porcella A, Marchese G, Casu MA, Rocchitta A, Lai ML, Gessa GL, Pani L.
Evidence for functional CB1 Cannabinoid receptor expressed in the rat thyroid
European Journal of Endocrinology, 2002, 147:255-261
48) Marchese G, Ruiu S, Casti P, Bartholini F, Saba PL, Gessa GL, Pani L.
Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central
effect.
European Journal of Pharmacology, 2002, 447:109-114
49) Marchese G, Bartholini F, Ruiu S, Casti P, Saba PL, Gessa GL, Pani L.
Effect of amisulpride isomers on rat prolactinemia
European Journal of Pharmacology, 2002, 448:263-266.
50) Casu M, Dinucci D, Colombo G, Gessa G, Pani L.
Reduced DAT- and DBH-immunostaining in the limbic system of Sardinian alcohol-preferring rats.
Brain Research, 2002, 948 :192-202
51) Pani L., Gessa G.L.
Dopaminergic deficit and Mood Disorders
International Clinical Psychopharmacology, 2002, 17 Suppl 4 : S1-S7
52) Pani L.
Clinical implications of dopamine research in schizophrenia.
Curr Med Res Opin. 2002;18 Suppl 3:s3-7.
53) Koukopoulos A. Sani G. Koukopoulos A.E. Minnai G.P Girardi P. Pani L. Albert M.J. Reginaldi D
Duration and Stability of the Rapid-Cycling Course: A Long-term Personal Follow-Up of 109 Patients
Journal of Affective Disorder, 2003, 73: 75-85
54) Ruiu S., Marchese G., Saba PL., Gessa GL., Vaccari A., Pani L.
In vitro evidence for the presence of [3H]-haloperidol uptake in rat brain.
Br J Pharmacol. 2003, 138:188-192
55) Congeddu E, Saba L, Porcella A, Sanna A, Marchese G, Lobina C, Gessa GL, Pani L.
Molecular characterization of new polymorphisms at the 2, 1, 2 GABAA receptor subunit genes
associated to a rat non-preferring ethanol phenotype.
Brain Res Mol Brain Res. 2003; 110:289-297.
56) Casu MA, Porcella A, Ruiu S, Saba P, Marchese G, Carai MA, Reali R, Gessa GL, Pani L.
Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract.
Eur J Pharmacol. 2003; 459:97-105.
57) Devoto D., Flore G., Vacca G., Pira L., Arca A., Casu M.A., Pani L., Gessa G.L.
Co-release of noradrenaline and dopamine from neuroadrenergic neurons in the cerebral cortex
induced by clozapine, the prototype atypical antipsychotic.
Psychopharmacol. 2003, 167:79-84.
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 8 / 27
Curriculum vitae
Luca Pani
58) Sanna A, Congeddu E, Porcella A, Saba L, Pistis M, Peis M, Marchese G, Lobina C, Grayson D,
Gessa GL, Pani L.
Characterization of wild-type (R100R) and mutated (Q100Q) GABAA 6 subunit in Sardinian alcohol
non-preferring rats (sNP).
Brain Res Mol Brain Res., 2003, 967:98-105
59) Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S, Casti P, Vargiu R, Pani L.
Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid
receptor.
J Pharmacol Exp Ther. 2003, 306: 363-370
60) Marchese G, Casti P, Ruiu S, Saba P, Sanna A, Casu G, Pani L.
Haloperidol, but not clozapine, produces dramatic catalepsy in Delta9-THC-treated rats: possible
clinical implications.
Br J Pharmacol. 2003, 140:520-526.
61) Marchese G, Bartholini F, Ruiu S, Casti P, Casu G, Pani L.
Ritanserin counteracts both rat vacuous chewing movements and nigro-striatal tyrosine hydroxylaseimmunostaining alterations induced by haloperidol
Eur J Pharmacol. 2004, 483: 65-69
62) Marchese G, Bartholini F, Casu MA, Ruiu S, Casti P, Congeddu E, Tambaro S, Pani L.
Haloperidol versus risperidone on rat “early onset” vacuous chewing
Behavioural Brain Research 2004, 149: 9-16
63) Casu MA, Pisu C, Lobina C, Pani L.
Immunocytochemical study of the forebrain serotonergic innervation in Sardinian alcohol-preferring
rats.
Psychopharmacology (Berl). 2004, 172: 341-351
64) Sanna A, Congeddu E, Saba L, Porcella A, Marchese G, Ruiu S, Casti P, Saba PL, Pani L.
The cerebellar GABAA 6 subunit is differentially modulated by chronic ethanol exposure in normal
(R100R) and mutated (Q100Q) sNP rats.
Brain Res. 2004 998:148-154
65) Ferrarini PL, Calderone V, Cavallini T, Manera C, Saccomanni G, Pani L, Ruiu S, Gessa GL.
Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new
ligands of cannabinoid receptors.
Bioorg Med Chem. 2004, 12:1921-1933.
66) Casti P, Marchese G, Casu G, Ruiu S, Pani L.
Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by
haloperidol in mice.
Neuropharmacology. 2004, 47:128-135.
67) Racagni G, Canonico PL, Ravizza L, Pani L, Amore M.
Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology. 2004,
50:134-143. Review.
68) Keith SJ, Pani L, Nick B, Emsley R, San L, Turner M, Conley R, Scully P, Chue PS, Lachaux B.
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.
Psychiatr Serv. 2004 55:997-1005.
69) Pira L, Mongeau R, Pani L.
The atypical antipsychotic quetiapine increases both noradrenaline and dopamine release in the rat
prefrontal cortex.
Eur J Pharmacol. 2004 Nov 3;504(1-2):61-4.
70) Tambaro S, Ruiu S, Dessi C, Mongeau R, Marchese G, Pani L.
Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays.
J Pharmacol Exp Ther. 2005 Feb;312(2):710-7.
71) Murineddu G, Ruiu S, Mussinu JM, Loriga G, Grella GE, Carai MA, Lazzari P, Pani L, Pinna GA.
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 9 / 27
Curriculum vitae
Luca Pani
Tricyclic pyrazoles.
Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands
for cannabinoid receptors.
Bioorg Med Chem. 2005 May 2;13(9):3309-20.
72) Saba L, Porcella A, Sanna A, Congeddu E, Marziliano N, Mongeau R, Grayson D, Pani L.
Five mutations in the GABA A alpha6 gene 5' flanking region are associated with a reduced basal and
ethanol-induced alpha6 upregulation in mutated Sardinian alcohol non-preferring rats.
Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):252-7.
73) Casu MA, Pisu C, Sanna A, Tambaro S, Spada GP, Mongeau R, Pani L.
Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an
immunohistochemical study.
Brain Res. 2005 Jun 28;1048(1-2):41-7.
74) Caboi F, Lazzari P, Pani L, Monduzzi M.
Effect of 1-butanol on the microstructure of lecithin/water/tripalmitin system.
Chem Phys Lipids. 2005 Jun;135(2):147-56.
75) Tambaro S, Mongeau R, Dessi C, Pani L, Ruiu S.
Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid
receptors.
Eur J Pharmacol. 2005 Nov 21;525(1-3):150-3.
76) Murineddu G, Ruiu S, Loriga G, Manca I, Lazzari P, Reali R, Pani L, Toma L, Pinna GA.
Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the
cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6
tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
J Med Chem. 2005 Nov 17;48(23):7351-62.
77) Murineddu G, Lazzari P, Ruiu S, Sanna A, Loriga G, Manca I, Falzoi M, Dessi C, Curzu MM,
Chelucci G, Pani L, Pinna GA.
Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective
CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2c]pyrazole-3-carboxamide.
J Med Chem. 2006 Dec 14;49(25):7502-12.
78) Casu MA, Sanna A, Spada GP, Falzoi M, Mongeau R, Pani L.
Effects of acute and chronic valproate treatments on p-CREB levels in the rat amygdala and nucleus
accumbens.
Brain Res. 2007, 1141, 15-24
79) Loriga G, Ruiu S, Manca I, Murineddu G, Dessi C, Pani L, Pinna GA
3-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}-6-substituted-3,6- diazabicyclo[3.1.1]heptanes as novel
potent dopamine uptake inhibitors
Bioorg Med Chem. 2007 Jun 1;15(11):3748-55.
80) Pani L, Pira L, Marchese G
Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy. Review.
Eur Psychiatry. 2007 Jul;22(5):267-75. Review.
81) Mongeau R, Marcello S, Andersen JS, Pani L
Contrasting effects of diazepam and repeated restraint stress on latent inhibition in mice
Behav Brain Res. 2007 Nov 2;183(2):147-55.
82) Mongeau R, Casu MA, Pani L, Pillolla G, Lianas L, Giachetti A.
Building a virtual archive using brain architecture and Web 3D to deliver neuropsychopharmacology
content over the Internet.
Comput Methods Programs Biomed. 2008 May;90(2):124-36.
83) Pani L, Villagrán JM, Kontaxakis VP, Alptekin K.
Practical issues with amisulpride in the management of patients with schizophrenia.
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 10 / 27
Curriculum vitae
Luca Pani
Clin Drug Investig. 2008;28(8):465-77.
84) Marchese G, Sanna A, Casu G, Casti P, Spada GP, Ruiu S, Pani L.
Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or
clozapine administration.
Eur J Pharmacol. 2008 Nov 19;598(1-3):16-20
85) Pani L and Marchese G.
Expected clinical benefits of paliperidone extended-release formulation when compared with
risperidone immediate-release.
Expert Opin Drug Deliv. 2009 Mar;6(3):319-31. Review.
86) Synthesis and in vitro Evaluation of Trifluoroethylamine Analogues of Enkephalins.
Sinisi R, Ghilardi A, Ruiu S, Lazzari P, Malpezzi L, Sani M, Pani L, Zanda M.
ChemMedChem. 2009 Sep;4(9):1416-20.
87) Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.
Olimpieri F, Tambaro S, Fustero S, Lazzari P, Sanchez-Roselló M, Pani L, Volonterio A, Zanda M.
Bioorg Med Chem Lett. 2009 Aug 15;19(16):4715-9.
88) Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting
risperidone administration in rats.
Marchese G, Casu G, Casti P, Spada GP, Pani L.
Eur J Pharmacol. 2009 Oct 12;620(1-3):36-41.
89) Oct4 expression in in-vitro-produced sheep blastocysts embryonic-stem-like cells.
Sanna D., Sanna A., Mara L., Pilichi S., Mastinu A., Chessa F., Pani L., Dattena M.
Cell Biol Int. 2009 Dec 16;34(1):53-60.
90) The need for individualised antipsychotic drug therapy in patients with schizophrenia.
Pani L.
Eur Rev Med Pharmacol Sci. 2009 Nov-Dec;13(6):453-459.
91) A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous
injection of risperidone free-base in rats.
Marchese G, Pittau B, Casu G, Peddio G, Spada GP, Pira M, Deriu A, Portesani F, Pisu C, Lazzari P,
Pani L.
Eur Psychiatry. 2010 Mar;25(2):92-100.
92) 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes
in mice.
Luongo L, Palazzo E, Tambaro S, Giordano C, Gatta L, Scafuro MA, Rossi FS, Lazzari P, Pani L, de
Novellis V, Malcangio M, Maione S.
Neurobiol Dis. 2010, 37: 177-185
93) Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF
mass spectrometry.
Falzoi M, Mossa A, Congeddu E, Saba L, Pani L.
Pharmacogenomics. 2010 Apr;11(4):559-71.
94) Antinociceptive activity of Delta9-tetrahydrocannabinol non-ionic microemulsions.
Lazzari P, Fadda P, Marchese G, Casu GL, Pani L.
Int J Pharm. 2010 Jun 30;393(1-2):238-43. Epub 2010 Apr 23.
95) Quetiapine anxiolytic-like effect in the Vogel conflict test is serotonin dependent.
Pisu C, Pira L, Pani L.
96) Weight loss induced by rimonabant is associated with an altered leptin expression and
hypothalamic leptin signaling in diet-induced obese mice.
Lazzari P, Sanna A, Mastinu A, Cabasino S, Manca I, Pani L.
Behav Brain Res. 2011 Mar 1;217(2):432-8. Epub 2010 Nov 11.
97) Unexplained somatic symptoms during major depression: prevalence and clinical impact in a
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 11 / 27
Curriculum vitae
Luca Pani
national sample of Italian psychiatric outpatients.
Perugi G, Canonico PL, Carbonato P, Mencacci C, Muscettola G, Pani L, Torta R, Vampini C, Fornaro
M, Parazzini F, Dumitriu A; Come To Me Study Group.
Psychopathology. 2011;44(2):116-24. Epub 2011 Jan 12.
98) Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across
571 major depressed outpatients.
Fornaro M, Maremmani I, Canonico PL, Carbonatto P, Mencacci C, Muscettola G, Pani L, Torta R,
Vampini C, Parazzini F, Dumitriu A, Perugi G.
Neuropsychiatr Dis Treat. 2011;7:217-21. Epub 2011 Apr 21.
99) Disclosure of grounds of European withdrawn and refused applications: a step forward on
regulatory transparency.
Tafuri G, Trotta F, Leufkens HG, Pani L.
Br J Clin Pharmacol. 2013 Apr;75(4):1149-51. doi: 10.1111/j.1365-2125.2012.04424
100) Are "social drugs" (tobacco, coffee and chocolate) related to the bipolar spectrum?
Maremmani I, Perugi G, Rovai L, Maremmani AG, Pacini M, Canonico PL, Carbonato P, Mencacci C,
Muscettola G, Pani L, Torta R, Vampini C, Akiskal HS.
J Affect Disord. 2011 May 21.
101) Novel approaches to drug-placebo difference calculation: evidence from short-term
antidepressant drug-trials.
Rihmer Z, Gonda X, Döme P, Erdős P, Ormos M, Pani L.
Hum Psychopharmacol. 2011 Jul 14. [Epub ahead of print] – I.F. 2.66
102) Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease:
Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden - Regulatory considerations
by European Medicines Agency focusing in improving benefit/risk in regulatory trials.
Isaac M, Vamvakas S, Abadie E, Jonsson B, Gispen C, Pani L.
Eur Neuropsychopharmacol. 2011 Sep 6 – I.F. 4.82
103) The placebo arm in clinical studies for treatment of Psychiatric Disorders: a regulatory Dilemma.
Gispen-de Wied C, Stoyanova V, Yu Y, Isaac M, Pani L, de Andres-Trelles F.
Eur Neuropsychopharmacol. 2012 Jun 14 [Epub ahead of print]
104) NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved
molecular profile.
Mastinu A, Pira M, Pani L, Pinna GA, Lazzari P.
Behav Brain Res. 2012 Oct 1;234(2):192-204. doi: 10.1016/j.bbr.2012.06.033. Epub 2012 Jul 4.
105) DSM-5 and clinical trials in psychiatry: challenges to come?
Butlen-Ducuing F, Haas M, Pani L, van Zwieten-Boot B, Broich K.
Nat Rev Drug Discov. 2012 Aug;11(8):583-4. doi: 10.1038/nrd3811.
106) Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 Ligands Using
Molecular Hybridization Based on Scaffold Hopping.
Murineddu G, Asproni B, Ruiu S, Deligia F, Falzoi M, Pau A, Thomas BF, Zhang Y, Pinna GA, Pani L,
Lazzari P.
Open Med Chem J. 2012;6:1-14. Epub 2012 May 17.
107) European licensing of maintenance treatment in schizophrenia.
Isaac M, Pani L, Gispen-de Wied C, Koch A.
Lancet. 2012 Aug 11;380(9841):562-3.
108) Discriminative hypomania checklist-32 factors in unipolar and bipolar major depressive patients.
Perugi G, Fornaro M, Maremmani I, Canonico PL, Carbonatto P, Mencacci C, Muscettola G, Pani L,
Torta R, Vampini C, Parazzini F, Dumitriu A, Angst J.
Psychopathology. 2012;45(6):390-8. doi: 10.1159/000338047. Epub 2012 Aug 7.
109) Disclosure of grounds of European withdrawn and refused applications: a step forward on
regulatory transparency.
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 12 / 27
Curriculum vitae
Luca Pani
Tafuri G, Trotta F, Leufkens HG, Pani L.
Br J Clin Pharmacol. 2013 Apr;75(4):1149-51. doi: 10.1111/j.1365-2125.2012.04424
110) Biosimilars: the paradox of sharing the same pharmacological action without full chemical identity
Pani L, Montilla S, Pimpinella G, Bertini Malgarini R.
Expert Opin Biol Ther. 2013 Jun 28. [Epub ahead of print]
111) High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From
the Italian Medicines Agency (AIFA).
Onder G, Bonassi S, Abbatecola AM, Folino-Gallo P, Lapi F, Marchionni N, Pani L, Pecorelli S,
Sancarlo D, Scuteri A, Trifirò G, Vitale C, Zuccaro SM, Bernabei R, Fini M; the Geriatrics Working
Group of the Italian Medicines Agency (AIFA).
J Gerontol A Biol Sci Med Sci. 2013 Aug 2. [Epub ahead of print]
112) Regulatory evaluation of Glybera in Europe - two committees, one mission.
Melchiorri D, Pani L, Gasparini P, Cossu G, Ancans J, Borg JJ, Drai C, Fiedor P, Flory E, Hudson I,
Leufkens HG, Müller-Berghaus J, Narayanan G, Neugebauer B, Pokrotnieks J, Robert JL,
Salmonson T, Schneider CK.
Nat Rev Drug Discov. 2013 Sep;12(9):719. doi: 10.1038/nrd3835-c1. Epub 2013 Aug 19.
113) Management of notifications of donors with Creutzfeldt-Jakob disease (post-donation
information).
Calizzani G, Vaglio S, Vetrugno V, Delbò M, Pani L, Grazzini G.
Blood Transfus. 2013 Oct 2:1-6. doi: 10.2450/2013.0035-13.
114) Stamina therapies: Let the record stand.
Bianco P, Cattaneo E, De Luca M, Pani L.
Nature. 2014 Feb 27;506(7489):434. doi: 10.1038/506434c
115) Management of notifications of donors with Creutzfeldt-Jakob disease (post-donation
information).
Calizzani G, Vaglio S, Vetrugno V, Delbò M, Pani L, Grazzini G.
Blood Transfus. 2014 Jan;12(1):22-7. doi: 10.2450/2013.0035-13. Epub 2013 Oct 2
116) Taking stock: A multistakeholder perspective on improving the delivery of care and the
development of treatments for Alzheimer's disease.
Bradley P, Akehurst R, Ballard C, Banerjee S, Blennow K, Bremner J, Broich K, Cummings J, Dening
K, Dubois B, Klipper W, Leibman C, Mantua V, Molinuevo JL, Morgan S, Muscolo LA, Nicolas F, Pani
L, Robinson L, Siviero P, van Dam J, Van Emelen J, Wimo A, Wortmann M, Goh L.
Alzheimers Dement. 2014 Apr 18. pii: S1552-5260(14)00033-8. doi: 10.1016/j.jalz.2014.01.007
117) Novel epigenetic target therapy for prostate cancer: a preclinical study.
Naldi I, Taranta M, Gherardini L, Pelosi G, Viglione F, Grimaldi S, Pani L, Cinti C.
PLoS One. 2014 May 22;9(5):e98101. doi: 10.1371/journal.pone.0098101. eCollection 2014.
118) Use and reimbursement of off-label drugs in pediatric anesthesia: the Italian experience.
Salvo I, Landoni G, Mucchetti M, Cabrini L, Pani L.
Paediatr Anaesth. 2014 Jun;24(6):625-31. doi: 10.1111/pan.12403. Epub 2014 May 3.
119) Coalition Against Major Diseases/European Medicines Agency biomarker qualification of
hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease.
Hill DL, Schwarz AJ, Isaac M, Pani L, Vamvakas S, Hemmings R, Carrillo MC, Yu P, Sun J, Beckett L,
Boccardi M, Brewer J, Brumfield M, Cantillon M, Cole PE, Fox N, Frisoni GB, Jack C, Kelleher T, Luo
F, Novak G, Maguire P, Meibach R, Patterson P, Bain L, Sampaio C, Raunig D, Soares H, Suhy J,
Wang H, Wolz R, Stephenson D
Alzheimers Dement. 2014 Jul;10(4):421-429.e3. doi: 10.1016/j.jalz.2013.07.003.
120) Towards a framework for treatment effectiveness in schizophrenia.
Juckel G, de Bartolomeis A, Gorwood P, Mosolov S, Pani L, Rossi A, Sanjuan J.
Neuropsychiatr Dis Treat. 2014 Sep 24;10:1867-78. doi: 10.2147/NDT.S61672. eCollection 2014
121) Managed entry agreements.
Muscolo LA, Bernardini C, Siviero PD, Montilla S, Pani L.
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 13 / 27
Curriculum vitae
Luca Pani
Orphanet J Rare Dis. 2014 Dec;9(1):844. doi: 10.1186/1750-1172-9-S1-O27
122) Are we ready? What is missing and what is needed? A regulator's perspective.
Bernardini C, Muscolo LA, Siviero PD, Montilla S, Pani L.
Orphanet J Rare Dis. 2014 Dec;9(1):842. doi: 10.1186/1750-1172-9-S1-O25
123) Changes and determination of dosing recommendations for medicinal products recently
authorised in the European Union.
Ehmann F, Papaluca M, Di Giuseppe F, Pani L, Eskova A, Manolis E, Herold R.
Expert Opin Pharmacother. 2015 Mar 14:1-9
124) Rare diseases and effective treatments: are we delivering?
Luzzatto L, Hollak CE, Cox TM, Schieppati A, Licht C, Kääriäinen H, Merlini G, Schaefer F, Simoens
S, Pani L, Garattini S, Remuzzi G.
Lancet. 2015 Feb 28;385(9970):750-2. doi: 10.1016/S0140-6736(15)60297-5.
125) Alternative pricing strategies for cancer drugs.
Messori A, De Rosa M, Pani L.
JAMA. 2015 Feb 24;313(8):857. doi: 10.1001/jama.2014.17814.
126) Steps forward in regulatory pathways for acute and chronic heart failure.
Pani L, Pecorelli S, Rosano G, Anker SD, Peracino A, Fregonese L, Prasad K, Rasi G.
Eur J Heart Fail. 2015 Jan;17(1):3-8. doi: 10.1002/ejhf.209
127) Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.
Savarese G, Perrone-Filardi P, D'Amore C, Vitale C, Trimarco B, Pani L, Rosano GM.
Int J Cardiol. 2014 Dec 3;181C:239-244. doi: 10.1016/j.ijcard.2014.12.017
128) Daptomycin in paediatrics: current knowledge and the need for future research.
Principi N, Caironi M, Venturini F, Pani L, Esposito S.
J Antimicrob Chemother. 2015 Mar;70(3):643-648. Epub 2014 Nov 17. Review
129) Transparency in medical research: Time for a paradigm shift.
Pelliccia F, Coats AJ, Pani L, Gaudio C, Rosano G.
Int J Cardiol. 2015 Mar 18;186:259-260. doi: 10.1016/j.ijcard.2015.03.21
130) The European Medicines Agency's strategies to meet the challenges of Alzheimer disease.
Haas M, Mantua V, Haberkamp M, Pani L, Isaac M, Butlen-Ducuing F, Vamvakas S, Broich K.
Nat Rev Drug Discov. 2015 Apr 1;14(4):221-2. doi: 10.1038/nrd4585.
131) Licensing of Generic Medicines: Are There Any Challenges Left? A Pharmaceutical Regulatory
Perspective. Borg JJ, Tomasi P, Pani L, Aislaitner G, Pirozynski M, Leufkens H, Melchiorri D. Sci
Pharm. 2014 May 22;82(4):847-56. doi: 10.3797/scipharm.1312-10. eCollection 2014 Dec.
132) Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4
inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555
patients from the Nationwide OsMed Health-DB Database. Fadini GP, Avogaro A,
Degli Esposti L, Russo P, Saragoni S, Buda S, Rosano G, Pecorelli S, Pani L; OsMed Health-DB
Network.
Eur Heart J. 2015 Jun 25. pii: ehv301
133) Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU
Regulators and the ECJ. Borg JJ, Laslop A, Pani L, Maciulaitis R, Melchiorri D.
Sci Pharm. 2014 Mar 24;82(3):541-54. doi: 10.3797/scipharm.1402-14. eCollection 2014 Sep.
134) Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance
database.
Renda F, Landoni G, Trotta F, Piras D, Finco G, Felicetti P, Pimpinella G, Pani L.
Int J Cardiol. 2015 Oct 22;203:217-220. doi: 10.1016/j.ijcard.2015.10.003.
135) Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide
Report From the Italian Medicines Agency.
Onder G, Marengoni A, Russo P, Degli Esposti L, Fini M, Monaco A, Bonassi S, Palmer K, Marrocco
W, Pozzi G, Sangiorgi D, Buda S, Marchionni N, Mammarella F, Bernabei R, Pani L, Pecorelli S;
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 14 / 27
Curriculum vitae
Luca Pani
Geriatrics Working Group of the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA);
Medicines Utilization Monitoring Center Health Database Network. J Am Med Dir Assoc. 2015 Sep
30. pii: S1525-8610(15)00535-6. doi: 10.1016/j.jamda.2015.08.009. [Epub ahead of print] PMID:
26441359
136) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data
from 10-Year Post-marketing Surveillance.
Renda F, Landoni G, Bertini Malgarini R, Assisi A, Azzolini ML, Mucchetti M, Pimpinella G, Pani L.
Drug Saf. 2015 Sep 14. PMID: 26370105
137) Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as
a test model.
Guarienti M, Giacopuzzi E, Gianoncelli A, Sigala S, Spano P, Pecorelli S, Pani L, Memo M.
Pharmacol Res. 2015 Sep 8;102:12-21. doi: 10.1016/j.phrs.2015.09.004. PMID:26361727
138) An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for
Erythropoietin.
Gianoncelli A, Bonini SA, Bertuzzi M, Guarienti M, Vezzoli S, Kumar R, Delbarba A, Mastinu A, Sigala
S, Spano P, Pani L, Pecorelli S, Memo M.
BioDrugs. 2015 Aug;29(4):285-300. doi: 10.1007/s40259-015-0136-3. PMID:26334631
139) Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer.
Messori A, De Rosa M, Fadda V, Pani L.
J Clin Oncol. 2015 Aug 24. pii: JCO.2015.61.8991
140) Identification and validation of biomarkers for autism spectrum disorders.
Loth E, Spooren W, Ham LM, Isaac MB, Auriche-Benichou C, Banaschewski T, Baron-Cohen S,
Broich K, Bölte S, Bourgeron T, Charman T, Collier D, de Andres-Trelles F, Durston S, Ecker C,
Elferink A, Haberkamp M, Hemmings R, Johnson MH, Jones EJ, Khwaja OS, Lenton S, Mason L,
Mantua V, Meyer-Lindenberg A, Lombardo MV, O'Dwyer L, Okamoto K, Pandina GJ, Pani L, Persico
AM, Simonoff E, Tauscher-Wisniewski S, Llinares-Garcia J, Vamvakas S, Williams S, Buitelaar JK,
Murphy DG
Nat Rev Drug Discov. 2015 Dec 31;15(1):70-3. doi: 10.1038/nrd.2015.7.
141) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A National Analysis of Data
from 10-Year Post-marketing Surveillance.
Renda F, Landoni G, Bertini Malgarini R, Assisi A, Azzolini ML, Mucchetti M, Pimpinella G, Pani L.
Drug Saf. 2015 Dec;38(12):1211-8. doi: 10.1007/s40264-015-0343-3.
142) Kounis Syndrome: An analysis of spontaneous reports from international pharmacovigilance
database.
Renda F, Landoni G, Trotta F, Piras D, Finco G, Felicetti P, Pimpinella G, Pani L.
Int J Cardiol. 2016 Jan 15;203:217-20. doi: 10.1016/j.ijcard.2015.10.003. Epub 2015 Oct 22
143) Advanced Age and Medication Prescription: More Years, Less Medications? A Nationwide
Report From the Italian Medicines Agency.
Onder G, Marengoni A, Russo P, Degli Esposti L, Fini M, Monaco A, Bonassi S, Palmer K, Marrocco
W, Pozzi G, Sangiorgi D, Buda S, Marchionni N, Mammarella F, Bernabei R, Pani L, Pecorelli S;
Geriatrics Working Group of the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA);
Medicines Utilization Monitoring Center Health Database Network.
J Am Med Dir Assoc. 2016 Feb;17(2):168-72. doi: 10.1016/j.jamda.2015.08.009
144) Balancing Access to Medicines and Sustainability in Europe: an Analysis from the Network of
Competent Authorities on Pricing and Reimbursement (CAPR).
Pani L, Montilla S, Németh G, Russo P, Viceconte G, Vogler S.
Pharmacol Res. 2016 Jun 9. pii: S1043-6618(16)30202-X. doi: 10.1016/j.phrs.2016.05.022
145) Pricing and Reimbursement experiences and insights in the EU and US: Lessons learned to
approach adaptive payer pathways.
Faulkner SD, Lee M, Qin D, Morrell L, Xoxi E, Sammarco A, Cammarata S, Russo P, Pani L, Barker
R.
Clin Pharmacol Ther. 2016 Sep 14. doi: 10.1002/cpt.508
146) Kounis syndrome due to antibiotics: A global overview from pharmacovigilance database.
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 15 / 27
Curriculum vitae
Luca Pani
Renda F, Marotta E, Landoni G, Belletti A, Cuconato V, Pani L.
Int J Cardiol. 2016 Sep 19;224:406-411. doi: 10.1016/j.ijcard.2016.09.066
Chapters in Book:
1) Rossetti Z.L.; Pani L. ; Portas C. ; Carboni S. ; Gessa G.L.
Evidence for D2-dopamine receptors modulating noradrenaline release in the rat frontal cortex in The
Basal Ganglia III,
Bernardi et al. Eds., 1990
2) Tondo L; Pani PP; Pani L; Carcassi L; Manconi PE; Rudas N.
T-Lymphocite in depression in: The modes of depression: from psychobiology to psychodynamics.
Ravizza, Genazzani,
Torta and Eva eds. Cortina. Torino, 1990
3) Costa E., Cheney D.L., Grayson D.R., Korneyev A., Longone P., Pani L., Romeo E.,
Zivkovich E., Guidotti A.
Pharmacology of Neurosteroids Biosynthesis: Role of the Mitochondrial DBI receptor (MDR) complex.
In Brain Corticosteroid Receptors : Studies on the Mechanism, Function, and Neurotoxicity of
Corticosteroid Action.
Vol. 746 of The Annals of the New York Academy of Sciences, 1994, 223-242
4) Serra G., Pani L., Collu M, Gessa G.L.
Ruolo delle Monoamine nella patogenesi dei disturbi dell’umore. In La depressione nel bambino e
nell’adolescente.
G. Lanzi et al. (eds) 1994, 179-192
5) Koukopoulos A.,Reginaldi D.,Minnai G., Serra G., Pani L., Johnson FN
The Long Term Prophylaxis of Affective Disorders in Depression and Mania: from Neurobiology to
Treatment,
Gessa GL, Fratta W., Pani L and Serra G. (eds), Raven Press, May 1995, 127-147
6) Gessa G.L., Pani L., Serra W., Fratta W
Animal Models of Mania in Depression and Mania: from Neurobiology to Treatment,
Gessa G.L., Fratta W., Pani L and Serra G. (eds), Raven Press, May 1995, 43-67
7) Gessa G.L., Serra G., Pani L.
Biochimica della Distimia : il ruolo della dopamina
Nuova Rivista di Neurologia, Suppl Vol. 5, 10-18 (1995)
8) Pani L., Gessa G.L.
The role of dopamine in the biological basis of dysthymia in Dysthymia in neurological disorders,
Proceedings of the WHO Meeting, J. Licinio; L. Prilipko and C.L. Bolis (eds), WHO Geneva,
Switzerland, 1997.
9) Pani L., Porcella A. and Gessa G.L.
Stress and the dopaminergic System in Stress and the nervous system, Proceedings of the WHO
Meeting,
J. Licinio and C.L. Bolis (eds), WHO Athens, Greece, 1998.
10) Serra G., Pani L., Gessa G.L.
Clozapina Enciclopedia Medica Italiana, Agg. II, Tomo I, 1284-1288, 1998
11) Pani L., Porcella A. and Gessa G.L.
Dysthymia: Psychosocial Aspects. in Dysthymia in Public Health, Proceedings of the Joint
WHO/AIREN Meeting,
J. Licinio and C.L. Bolis (eds), WHO Geneva, Switzerland, In press, 1999.
12) Pani L., Porcella A, Gessa G.L.
Hypothesis testing: dopaminergic system, environmental pressure and evolutionary mismatch, in
Dopaminergic System:
Evolution from Biology to Clinical Aspects,
Bolis CL, Pani L and Licinio J. (eds) Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 16 / 27
Curriculum vitae
Luca Pani
13) Gessa G.L., Pani L, Devoto P
Is dopamine in the prefrontal cortex released from noradrenergic neurons? in
Dopaminergic System: Evolution from Biology to Clinical Aspects, Bolis CL, Pani L and Licinio J. (eds)
Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001
14) Pani L, Biggio G
Effetti collaterali delle benzodiazepine in Benzodiazepine dalle molecole alla pratica clinica,
Biggio G, (ed), Springer-Verlaag Italia, Milano 2001
15) Canali S, De Anna G, Pani L
Evolutionary Psychopharmacology mental disorders and ethical behaviour in:
Evolutionary ethics and contemporary Biology, Boniolo G, (ed) Cambridge University Press
Cambridge, 2006
16) Pani L, Saba L
Farmacogenetica degli Antipsicotici in:
Trattato Italiano di Psichiatria, Cassano GB (ed), Masson-Elsevier, Milano 2008
17) Salloum IM, Pani L, Cooke T
Management of Comorbidity in Bipolar Disorder in:
Bipolar Disorder: Clinical and Neurobiological Foundations, Edited by Lakshmi N. Yatham and Mario
Maj, John Wiley & Sons, 2010
Books:
1) Gian Luigi Gessa e Luca Pani
Il ruolo della dopamina nei disturbi depressivi Parte Prima: Neurobiologia della Distimia: il ruolo della
dopamina.
Mediserve Milano, 1998 (I edizione)
2) Luca Pani e Gian Luigi Gessa
Il ruolo della dopamina nei disturbi depressivi Parte Seconda Distimia: diagnosi e trattamento.
Mediserve Milano, 1998 (I edizione)
3) Gian Luigi Gessa e Luca Pani
Il ruolo della dopamina nei disturbi depressivi. Volume Unico
Mediserve Milano, 1999 (II edizione)
4) Gerardo Medea e Luca Pani
I Disturbi depressivi in Medicina Generale. Diagnosi e Gestione
UTET Periodici Milano, 2000
5) Luca Pani
La Biochimica del Cervello
Masson, Milano 2001
6) Stefano Canali e Luca Pani
Emozioni e malattia. Dall’evoluzione biologica al tramonto del pensiero psicosomatico
Paravia Bruno Mondadori Editori, Milano 2003
7) Luca Pani
Distimia: dal temperamento alla malattia
Masson, Milano 2004
8) Luca Pani
La Rivoluzione di Paul Janssen
Cinquant’anni di Terapia della Schizofrenia: dall’aloperidolo al paliperidone
Elsevier, Milano 2009
9) Pani L., Martinez F.
Prove di Volo: Manuale di Psiconautica Elementare.
Edra, Milano, MILANO, Ottobre 2015
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 17 / 27
Curriculum vitae
Luca Pani
10) Pani L., Corbellini
Imperfezioni Umane
Rubbettino, CATANZARO, Ottobre 2015
11) Pani L.
L’innovazione sostenibile
Edra, Milano, MILANO, Gennaio 2016
12) Pani L.
Sustainable Innovation
Edra, Milano, MILANO, June 2016
12) Pani L., (dipinti di Martinez F.)
Prove di Volo II: Manuale di Psiconautica Normale.
Edra, Milano, MILANO, Ottobre 2016
Editor of Books:
1) Depression and Mania: from Neurobiology to Treatment,
Gessa GL, Fratta W., Pani L and Serra G. (eds),
Raven Press, New York, 1995
2) Psicofarmacologia Essenziale, Basi Neuroscientifiche e Applicazioni Pratiche di Stephen M. Stahl;
I Edizione Italiana a cura di: Luca Pani e Gian Luigi Gessa, Centro Scientifico Editore, Torino, 1999
3) Dopaminergic System: Evolution from Biology to Clinical Aspects
Bolis CL, Pani L and Licinio J. (eds)
Lippincott Williams & Wilkins Healthcare, Philadelphia, 2001
4) Psicofarmacologia Essenziale, Basi Neuroscientifiche e Applicazioni Pratiche di Stephen M. Stahl;
II Edizione Italiana a cura di: Luca Pani e Gian Luigi Gessa, Centro Scientifico Editore, Torino, 2002
5) Psicofarmacologia Essenziale, Basi Neuroscientifiche e Applicazioni Pratiche di Stephen M. Stahl;
III Edizione Italiana a cura di: Luca Pani, Edi-Ermes, Milano, 2011
6) Depressione e Disturbi Bipolari estratto da Psicofarmacologia Essenziale, Basi Neuroscientifiche e
Applicazioni Pratiche di Stephen M.Stahl; Ediz. Italiana a cura di: Luca Pani, Edi-Ermes Milano 2011
International (IN RED) or National Consultation/Advisory Boards, Invited Lectures, Teaching and
Presentation at Continuous Medical Education Courses (CME).
Projects
Luca Pani is one of the inventors (does not have ownership) of two new U.S. and one E.C. Patents
namely:
US2010029622A1 (Feb, 4 – 2010) on Microemulsion
US2010028257A1 (Feb, 4 – 2010) on Novel Omepiperazines Opioids
EP2223681A1 (Feb, 24 - 2010) on Composition of spores of non pathogenic bacteria
Memberships
Since 1994, Luca Pani has been invited to give presentation in more than 1000 Conferences,
Seminars, Expert Opinion, Round Tables etc etc. Please note the following events:
Member of Educational / Editorial Strategic Boards: not product specific and open to delegates
primarily health care professionals and organized though a provider of medical education to
pharmaceutical companies
Speaker in Medical Education Events : such events were not product specific, open to all delegates
(healthcare professionals), without restriction, and focused on psychopharmacology (animal models,
relationship between PK profiles and clinical impact).
I was involved as a paid speaker in some of these events, and in some cases the participation was
together with other experts in the field.
Jan 17-20, 2011 London (UK) CHMP Meeting European Medicines Agency
Jan 24, 2011 Rome (I) Trainining to Mentors: Teaching with Algorithms The INVERITAS 2011 Project
Jan 25, 2011 Arcugnano (I) CME course: Evoluzione e traiettorie della Schizofrenia e del Disturbo
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 18 / 27
Curriculum vitae
Luca Pani
Bipolare: uso degli antipsicotici
Jan 31- Feb 1, 2011 London (UK) SAWP Meeting European Medicines Agency
Feb 14-17, 2011 London (UK) CHMP Meeting European Medicines Agency
Feb 10-11 2011 Pula (I) Center of Excellence Meeting
Feb 14-17, 2011 London (UK) CHMP Meeting European Medicines Agency
March 2–4, 2011 London (UK) SAWP Meeting European Medicines Agency
March 5, 2011 Nice (FR) ECNP-EMA Assessor Meeting
March 6-7 2011 Nice (FR) ECNP-EFPIA Summit Meeting
March 10-11, 2011 Pula (I) Center of Excellence Meeting (Chair and Speaker)
March 14-17, 2011 London (UK) CHMP Meeting European Medicines Agency
March 23, 2011 Sorrento (I) CME course: Evoluzione e traiettorie della Schizofrenia e del Disturbo
Bipolare: uso degli antipsicotici
March 24-25, 2011 Siena (I) ME Course: Zipswitch Algorithm on how to switch between
antipsychotics
March 28-30, 2011 London (UK) SAWP Meeting European Medicines Agency
April 4, 2011 London (UK) CNSWP Plenary Meeting
April 11-14, 2011 London (UK) CHMP Meeting European Medicines Agency
April 26-28, 2011 London (UK) SAWP Meeting European Medicines Agency
May 16-19, 2011 London (UK) CHMP Meeting European Medicines Agency
May 23-26, 2011 London (UK) SAWP Meeting European Medicines Agency
June 20-22, 2011 London (UK) CHMP Meeting European Medicines Agency
June 27-30, 2011 London (UK) SAWP Meeting European Medicines Agency
July 1, 2011 London (UK) Tapestry Network Alliance for Alzheimer
July 12, 2011 London by TC CNSWP Meeting European Medicines Agency
July 14-15, 2011 Rome (I) AIFA Study Section on Independent Research
July 18-20, 2011 London (UK) CHMP Meeting European Medicines Agency
Aug 30–31, 2011 London (UK) SAWP Meeting European Medicines Agency
Sep 1, 2011 Paris (FR) Symposium on Human Motivation (Speaker)
Sep 2, 2011 London (UK) Extra-CHMP Meeting European Medicines Agency
Sep 9, 2011 Miami (USA) University of Miami School of Medicine – Lecture Psychiatric Residents
Sep 16, 2011 Miami (USA) University of Miami School of Medicine – Lecture Psychiatric Residents
Sep 19-22, 2011 London (UK) CHMP Meeting European Medicines Agency
Sep 22, 2011 London (UK) CNSWP Meeting European Medicines Agency
Sep 23, 2011 London (UK) DSM-5 Meeting European Medicines Agency with FDA
Sep 26-28, 2011 London (UK) SAWP Meeting European Medicines Agency
Oct 3, 2011 Rome by TC Fase 1 Comitato Tecnico Scientifico
Oct 5, 2011 London (UK) Head Medicines Agency Informal Board Meeting at EMA
Oct 6, 2011 London (UK) Management Board Meeting of EMA
Oct 13-14, 2011 Rome (I) TOPRA Meeting
Oct 17-18, 2011 London (UK) CHMP Meeting European Medicines Agency
Oct 24-27, 2011 London (UK) SAWP Meeting European Medicines Agency
Nov 14, 2011 Rome (I) Fase 1 – Comitato Tecnico Scientifico
Nov 14-17, 2011 London (UK) CHMP Meeting European Medicenes Agency
Nov 28-30, 2011 London (UK) SAWP Meeting European Medicines Agency
Dec 12-14, 2011 London (UK) CHMP Meeting European Medicines Agency
Dec 15 2011 London (UK) Management Board Meeting of EMA
Dec 19 2011 Rome (I) Fase 1 – Comitato Tecnico Scientifico
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 19 / 27
Curriculum vitae
Luca Pani
Jan 20, 2012 Rome (I) Simposio Internazionale: The biopolar spectrum from somatic illness to manicdepressive illness
Jan 23 2012 Rome (I) Fase 1 – Comitato Tecnico Scientifico
Jan 30- Feb 2, 2012 London (UK) SAWP Meeting European Medicines Agency
Feb 14, 2012 Rome (I) Promuovere la Medicina Traslazinale attraverso le infrastrutture dedicate alla
Salute e alla Ricerca
Feb 23-24, 2012 Copenhagen (DK) Heads of Medicines Agencies Meeting (HMA)
Feb 27 – March 2,2012 London (UK) SAWP Meeting European Medicines Agency
March 8, 2012 Rome (I) Comitato Tecnico Scientifico
March 12-15, 2012 London (UK) CHMP Meeting European Medicines Agency
March 21-22, 2012 London (UK) Management Board Meeting of EMA
April 2, 2012 Rome (I) Secondo Seminario di Alta formazione in preparazione sanitaria su: analisi
delle caratteristiche e della demografia del personale del Servizio Sanitario Nazionale
April 17, 2012 Rome (I) Seminario del Forum per la Ricerca Biomedica sull'innovazione e la ricerca in
campo sanitario e farmacologico
April 23-26, 2012 London (UK) SAWP Meeting European Medicines Agency
May 10, 2012 Rome (I) About Pharma Focus on Farmaci Generici e innovatività: tra sostenibilità e
sviluppo
May 10-11, 2012 Rome (I) HTA e decision making
May 11, 2012 Rome (I) Fase 1 – Comitato Tecnico Scientifico
May 23, 2012 Geneva (CH) Seminario Sanitary Regulation - challenges in a world without borders:
improving cooperation Drug Regulatory Agencies - WHO
May 25, 2012 Chia Laguna (I) 5° Forum Nazionale SIF
May 28-29, 2012 London (UK) SAWP Meeting European Medicines Agency
May 31-June 1, 2012 Rimini (I) 52° Simposio Annuale AFI
June 19-20, 2012 Copenhagen Heads of Medicines Agencies Meeting (HMA)
June 21-22, 2012 Rome (I) Generici e Biosimilari
June 25-28, 2012 Philadelphia (USA) DIA Annual Meeting
July 2, 2012 (I) Round table I-com
Juy 3, 2012 Rome (I) 4° Convegno Nazionale della Public Affairs Association
July 5, 2012 Rome (I) Convegno Analisi della prescrizione farmaceutica in Italia
August 20-23, 2012 London (UK) SAWP Meeting European Medicines Agency
September 20-21, 2012 Cyprus (EL) Heads of Medicines Agencies Meeting (HMA)
October 7, 2012 Milan (I) 46° Congresso Nazionale SIP
October 9, 2012 Rome (I) Roundtable – Le prospettive del Princing del Farmaco in Italia(I-COM)
October 11-14, 2012 Bari (I) XXXIII Congresso Nazionale SIFO
October 22-24, 2012 London (UK) SAWP Meeting European Medicines Agency
October 30, 2012 Rome (I) Conferenza Stampa “Farmaci biologici e farmaci biosimilari: tutelare i
pazienti, difendere i brevetti, promuovere l’innovazione, garantire il risparmio. DDL 1875"
November 6, 2012 Rome (I) Seconda Conferenza Nazionale sul Diabete
November 12-13, 2012 Cernobbio (I) 3a Conferenza Nazionale sulla Ricerca Sanitaria
November 17, 2012 Bari (I) Welfare e Sanità
November 23, 2012 Rome (I) Informal Meeting COMP and PDCO
November 22-24, 2012 Florence (I) 29° Congresso Nazionale SIMG
November 24-29, 2012 Manaus (BR) 7th Summit of Heads of Medicines Regulatory Agencies
December 5-6,2012 Rome (I) V Conferenza Nazionale sui Dispositivi Medici
December 10, 2012 Rome (I) 109° Conferenza Permanente dei Presidenti di Consiglio di Corso di
Laurea Magistrale in Medicina e Chirurgia
December 11, 2012 Rome (I) Relazione sullo Stato Sanitario del Paese per l’anno 2011
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 20 / 27
Curriculum vitae
Luca Pani
December 13, 2012 London (UK) EMA Management Board
December 19, 2012 Rome (I) Programma Nazionale in materia sanitaria “Le idee per la sanità del
futuro. Un confroto aperto con gli operatori del settore.
January 10, 2013 Catania (I) Dodicesima Conferenza Nazionale sulla farmaceutica
January 14-16,2013 Milan (I) 1st ESTRO Congress
January 28-31, 2013 London (UK) SAWP Meeting European Medicines Agency
February 5, 2013 London (UK) EMA - MBTC meeting
February 8, 2013 Rome (I) Farmaci. Diritto di Parola
February 14-16, 2013 Rome (I) Gender and Science
February 28, 2013 Rome (I) Giornata Mondiale delle Malattie Rare
March, 4-8, 2013 Amsterdam (NL) Dia Euromeeting
March, 8-9 March, 2013 PIetrasanta (I) AMEF 2013 – Expert Forum on Addiction Medicine
March 25, 2013 Rome (I) Meridiano Sanità – Diabete 2020
April 23-24, 2013 Dublin (IRL) Heads of Medicines Agencies Meeting (HMA)
May 3, 2013 Bari (I) Giornata su Farmaco e Prodotti per la Salute
May 6-7, 2013 London (UK) SAWP Meeting European Medicines Agency
May 8, 2013 Bologna (I) 69° Congresso Nazionale della Società Italiana di Pediatria
May 28, 2013 Dublin (IRL) Health Brain Conference (European Commission)
May 29-31, 2013 Chia Laguna (I) 6° Forum Nazionale Pharma
June 3-5, 2013 London (UK) SAWP Meeting European Medicines Agency
June 8, 2013 Rome (I) New trends in cardiovascular drug therapy
June 13, 2013 London(UK) Management Board Meeting of EMA
June 23-25,2013 Boston (USA) DIA Annual Meeting
July 2, 2013 Rome (I) Tavola Rotonda “Riflessioni sui 10 anni passati e (forse) futuri di federalismo
sanitario in Italia” – I-Com Istituto per la competitività
July 3, 2013 Rome (I) L'industria del farmaco: innovazione continua. Ricerca, produzione,
occupazione per la crescita del Paese. Farmindustria
July 8-10, 2013 London (UK) SAWP Meeting European Medicines Agency
July 13, 2013 Cortina (I) 1st Annual MGH CTNI Europe Meeting on CNS Drug Development
July 16, 2013 Rome (I) Appropriatezza clinica strumentale e operativa nella prevenzione, diagnosi e
terapia dei disturbi dell'alimentazione
August 25-28 2013 Seattle (USA)
IDRI Meeting September 3-5, 2013 London (UK)
SAWP Meeting European Medicines Agency September 6, 2013 London (UK) Workshop on Conflict
of Interest
September 10, 2013 Vilnius (Lithuania) 73rd HMA Meeting, 10th September 2013
September 17-19 2013 Washington (USA) Workshop on "Ensuring the Safety and Quality of the
Global Supply Chain for Medicines: Regulatory Challenges and Lessons from Other Sectors,"
sponsored by the Council on Foreign Relations (CFR)
September 20, 2013 Pula (Cagliari) Incontro con i principali player del distretto Biomed regionale in
Sardegna
September 25-26, 2013 Rome (I) 36° Annual WHO
September 26, 2013 Rome (I) CREA Sanità - Presentazione IX Rapporto Sanità
September-October 30-09/2, 2013
London (UK) SAWP Meeting European Medicines AgencyOctober 3, 2013
London (UK) Management Board Meeting of EMA
October 4, 2013 London (UK) CNS Working Party
October 8, 2013 Rome (I) Premio letterario Leggi in Salute Angelo Zanibelli
October 10, 2013 Padua (I) 3° Congresso Nazionale sulla Medicina di Genere
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 21 / 27
Curriculum vitae
Luca Pani
October 13, 2013 Bergamo (I) BERGAMO SCIENZA XI EDIZIONE
October 14, 2013 Sassari (I) La funzione delle agenzie regolatorie nello sviluppo del farmaco –
Università di Sassari Dipartimento di Scienze Biomediche
October 15, 2013 Rome (I) Presentazione libro Censis: Disponibilità e Certificazione dei dati statistici
in Sanità
October 16, 2013 Rome (I) Convegno “Federalismo in (poca) salute: una ricetta da riscrivere”
October 16, 2013 Rome (I) Festa nazionale del Medico di famiglia
October 16, 2013 Torino (I) XXXIV Congresso Nazionale SIFO
October 23, 2013 Torino (I) 36° Congresso della Società Italiana di Farmacologia (SIF)
October 26, 2013 Rome (I) XLII Congresso Nazionale ANMIRS “Il mercato della speranza. Quando
terapie non efficaci vengono utilizzate lo stesso”
October 31, 2013 Rome (I) “La salute di genere: una proposta per il futuro” ISS
November 4-5,2013 London (UK) SAWP Meeting European Medicines Agency
November 6,2013 London (UK) EU Telematics Management Board (EU TMB)
November 9,2013 Bari (I) IX Edizione del Caduceo d'Oro
November 12,2013 Padova (I) Symposium Facing a Revolution in HCV Therapy
November 21,2013 Firenze (I) 30° Congresso Nazionale della Società Italiana di Medicina Generale SIMG
November 22, 2013 Pisa (I) Terapie avanzate: armonizzare regole e innovazione per nuove
opportunità di cure FARMINDUSTRIA
November 22,2013 Rome (I) La Malattia Maniaco-Depressiva: l’eredità di Athanasios Koukopoulos.
Azienda Ospedaliera Sant’Andrea
November 23, 2013 Rome (I) FACE-TO-FACE HIV. Fondazione ICONA
November 24-25, 2013 Rome (I) Workshop on Heart Failure. Fondazione Lorenzini
November 26 2013 London (UK) EMA/HTA Parallel Scientific Advice Workshop; CNS Working party
November 26-28, 2013 London (UK) SAWP Meeting European Medicines Agency
November 30, 2013 Rimini (I) II congresso corte di giustizia popolare per il diritto alla salute FEDERANZIANI
December 3, 2013 London (UK) “Adaptive Pathways for Personalised Medicines – Supporting
Innovation in Europe”
December 4-6, 2013 Amsterdam (NL) Summit 2013 Amsterdam 8th International Summit of Heads of
Medicines Regulatory Agencies
December 8, 2013 Naples (I) Melanoma Bridge 2013
December 11-12, 2013 London (UK) Management Board Meeting of EMA
February 3-5, 2014 London (UK) SAWP Meeting European Medicines Agency
February 8, 2014 Florence L'ANMCO delle idee: scienza e organizzazione per la Sanità del Futuro
February 13, 2014 London (UK) 4th Annual Symposium Relativity in the Evaluation of Medicines
February 18-22, 2014 Washington (USA) 10th Annual Scientific Meeting (ISCTM)
February 25, 2014 Brussels (B) EURORDIS Price for Innovation
February 28, 2014 Rome (I) Dalla Ricerca scientifica alla tutela delle persone con malattie rare
March 3-5, 2014 London (UK) SAWP Meeting European Medicines Agency
March 12-13, 2014 Rome (I) 3° Convegno Nazionale sulla Ricerca Indipendente in Italia - FADOI
March 14, 2014 Rome (I) Unistem Day 2014 Università La Sapienza
March 17, 2014 Rome (I) Horizon 2020 - Sfida Sociale "Health welbeing and demographic changes" :
opportunità di ricerca per sviluppare crescita sostenibile e competitività
March 19-20, 2014 London (UK) Management Board Meeting of EMA
March 31, 2014 Rome (I) Unistem Day 2014
March 31 - April 2, 2014 London (UK) SAWP Meeting European Medicines Agency of EMA
April 2-3, 2014 London (UK) Global Updates on Accelerated Acess to Innovativ Medicines for Patients
in Need. Workshop Co-hosted by EMA, IMI, EFPIA MIT Newdigs
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 22 / 27
Curriculum vitae
Luca Pani
April 4, 2014 Latina (I) Farmindustria. Produzione di Valore. L'industria del Farmaco: un patrimonio
che l'Italia non può perdere.
April 4-5-6, 2014 Rome (I) Terzo incontro del Congresso Mondiale per la Libertà di Ricerca Scientifica
April 5-9, 2014 Florence (I) 4th Schizophrenia International Research Society Conference
April 8-9, 2014 Rome (I) Stati Generali della Salute
April 11,2014 Naples (I) 3rd Meeting on External Quality Assessment in Molecular Pathology
April 10-12, 2014 Foligno (I) IV Festa Scienza e Filosofia
April 15, 2014 Rome (I) Le applicazioni delle cellule staminali in medicina rigenerativa - III Incontro del
Ciclo: " Scienza, Innovazione e Salute". Senato della Repubblica. Commissione Igiene e Sanità
April 28, 2014 Milan (I) Audizione Indagine Conoscitiva sul metodo Stamina
April 29, 2014 Rome Giornata a tema: la Medicina e la sperimentazione animale. Accademia Medica
di Roma.
May 9, 2014 Berlin (DE) The European Conference on Rare diseases & Orphan products (ECRD
2014)
May 15-16, 2014 Paris (FR) Clinical Trials
May 20, 2014 Bari (I) Farmindustria: Produzione di Valore
May 21, 2014 Geneva (CH) International Coalition of Medicines Regulatory Authorities Meeting
(ICMRA) at the WHO Health Assembly
June 4-5, 2014 Catania (I) La Terapia con cellule staminali tra realtà e finzione
June 11-12, 201 4 London (UK) Management Board Meeting of EMA
June 13, 2014 London (UK) International Coalition of Medicines Regulatory Authorities Meeting
(ICMRA) Interim Management Commitee Meeting
June 16-19, 2014 San Diego (USA) DIA Annual Meeting
June 27,2014 2nd Annual CTNI European Symposium Harvard University, Massachusetts General
Hospital
June 30, 2014 Catanzaro (I) Possibilità di accesso alle cure nella Regione Calabria tra Innovazione e
Sostenibilità
July 8-9, 2014 London (UK) SAWP meeting European Medicine Agency
July 10, 2014 Monteporzio Catone (I) 7th Italian Barometer Diabetes Forum
July 15-16-17 Rome (I) 77th HMA Meeting
August 23, 2014 Rio de Janeiro ICMRA meeting
September 1-2, 201 London (UK) SAWP Meeting European Medicine Agency
September 6, 2014 Cagliar (I) i Premio Navicella
September 10, 2014 Rome (I) EAGEN Postgraduate Course Advances and gut microbiota and fecal
microbiota transplantation
September 17, 2014 Brussels Informal meeting on evaluation and pricing of new hepatitis C
medicines
September 19, 2014 Rome (I) XI Congresso delle libertà civili dell'Associazione Luca Coscioni per la
libertà di ricerca scientifica
September 21-22, 2014 Milan (I) Informal EPSCO Health Event Innovative Systems and Health
Horizons
September 24, 2014 Rome (I) Il decalogo dei farmaci biosimilari: 10 affermazioni da cui partire
September 25, 2014 Rome (I) La lotta all’epatite al banco di prova delle richieste dei pazienti e dei
bisogni del sistema salute
September 26, 2014 Florence (I) Toscana Pharma & Devices Valley
September 26-27, 2014 Cagliari (I) 5° Congresso Regionale AIP: Prevenzione e Cura in
Psicogeriatria
September 28, 2014 Cagliari (I) Congresso Isola Donna al centro del mondo medico e sociale
September 30, 2014 Rome (I) PRAC Informal Italian Presidency Meeting
October 1-2, 2014 London (UK) Management Board Meeting of EMA
October 3, 2014 Tolosa (FR) Workshop Euopean Science Foundation
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 23 / 27
Curriculum vitae
Luca Pani
October 6-7, 2014 London (UK) SAWP Meeting European Medicine Agency
October 8, 2014 Rome (I) WGEO
October 9, 2014 Rome (I) Premio Letterario Legge in Salute
October 11, 2014 Rome (I) Giornata Europea per la Donazione degli Organi (European Organ
Donation Day – EODD)
October 15, 2014 Rome (I) Roundtable I-Com "Le nuove frontiere della remunerazione del farmaco.
Innovazione evidenza clinica e personalizzazione della terapia”
October 15, 2014 Rome (I) Piano Nazionale sulle demenze
October 16-17, 2014 Rome (I) Informal PDCO / SAWP meeting
October 18, 2014 Rome (I) Neuro Enhancement - Le Ricerche in Italia
October 20, 2014 London (UK) IMI/CASMI IMIPACT Stakeholder Platform
meeting
October 22, 2014 Rome (I) Ambasciata America: Life Sciences Industry: il futuro è oggi European
Cimmission Multistakeholders workshop on farmecutical industry
October 23-24, 2014 Rome (I) Italia 2014.EU Metting of the network of competent authorityes for
pricing and reinvursement (CAPR)
October 24-25, 2014 Milan (I) Epatite C: Incontro informativo
October 28, 2014 Rome (I) Conferenza Ministeriale “Health in the Mediterranean”
October 28, 2014 Perugia (I) Geopolitica della Salute, farmaci sanità e popolazione nel mondo
globalizzato
October 29-30, 20014 Rome (I) CHMP, CAT, COMP, Joint Presidency meeting
October 30, 2014 Rome (I) HTA Europe
October 31, 2014 San Giovanni Rotondo (I) Innovazione, teconolgia emedicnina personalizzata: la
sfida della sostenibilità tecnologica, economica, bioetica e sociale.
November 3, 2014 Rome (I) 2014. EU The State of Health of vaccination in the EU
November 4-5, 2014 Rome (I) 2014. EU Strategic presidency meeting of the Herbal Mecidinal
Products Committee (HMPC)
November 6-7, 2014 Rome (I) 2014. EU 42TH European Medicines Agencies – operation on legal
and legislative issues (Emacolex) meeting
November 8, 2014 Bari (I) Decima edizione Caduceo 2014
November 10, 2014 Lausanne (CH) Dementia Integrated Development
November 13, 2014 Miami (USA) CNS Summit 2014
November 19-21, 2014 China 9th Summit of Heads of Medicines Regulatory Agency
November 22, 2014 Fiuggi (I) Il Forum Italiano sulla Fibrosi Cistica
November 24-25, 2014 Londn (UK) EMA Workshop on Alzheimer's Diseases
November 26-28, 2014 Rome (I) 78th HMA Meeting
November 27-29,2014 Florence (I) 31° Congresso Nazionale SIMG "La Società Italiana di Medicina
Generale e delle Cure primarie
December 2-3, 2014 London (UK) SAWP European Medicine Agency
December 4-5, 2014 London (UK) Dose Workshop at EMA
December 8-9, 2014 Washington (USA) Workshop on Regulatory pathways in caxexia
December 10, 2014 Rome (I) Heads of Medicines Agencies - Working Group of Communicazio
Professionals
December 13-15, 2014 Rome (I) Comitato d'Onore e Cerimonia Inaugurale SIC 2014
December 15, 2014 Rome (I) Innovazione Health in Progress my talk
December 15, 2014 Rome (I) IBL Seminario "Il Caso Avastin/Lucentis: la regolazione del commercio
dei farmaci, tra tutela della salute e vincoli di spesa pubblica"
December 18, 2014 Rome (I) VII Conferenza Nazionale sui Dispositivi Medici
January 15, 2015 Convegno "Le Biotecnologie per la salute: innovazione, competenze e sostenibilità"
January 28, 2015 London (UK) Meeting with industry on the Telematics strategy: pre-meeting with
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 24 / 27
Curriculum vitae
Luca Pani
regulators only
January 28, 2015 Venice (I) Motore Sanità - Stati Generali della Sanità-Regione Veneto
February 2-3, 2015 London (UK) SAWP Meeting European Medicine Agency
February 4-5, 2015 Latvia Heads of Medicines Agencies Meeting (HMA)
February 8, 2015 Bari (I) Ordine dei Farmacisti Farmacovigilanza: Servizio sanitario Nazionale e
politica farmaceutica: il ruolo del farmacista e della farmacia
February 11, 2015 Rome (I) Presentazione Italian Barometer Diabetes Report 2014
February 11, 2015 Rome (I) Ambrosetti Club: Cambiamenti in atto e prospettive future nel sistema di
valutazione e regolamentazione dell’innovazione scientifica e tecnologica
February 17, 2015 Latina (I) Investire in salute per rilanciare l'economia
February 20, 2015 Rome (I) AISF - Chronic Hepatitis C: a global approach
February 24, 2015 Rome (I) COM (Istituto per la Competitività) PHARMAITALIA 2015: I Cambiamenti
attesi nella governance: dell’assistenza farmaceutica per la sostenibilità del SSN.
March 1-6, 2015 Venice (I) ECNP School of Child and Adoloscent Neuropsychopharmacology
March 9-10, 2015 London (UK) SAWP Meeting European Medicine Agency
March 11, 2015 London (UK) EU Telematics Management Board
March 13, 2015 Milan (I) UniStem Day
March 13-14, 2015 Florence (I) Convegno Internazionale su Ricerca in Pediatrica
March 16, 2015 I-HEALTH e E-HEALTH: come tramutare le opportunità della sanità digitale in un
miglioramento degli attuali servizi sanitari
April 2, 2015 Foggia (I) Seminario di studio sul tema la sostenibilità economica dei prodotti della
ricerca: i farmaci innovativi
April 7-9, 2015 London (UK) SAWP Meeting European Medicine Agency
April 10, 2015 Rome (I) 1° Forum EUPATI National Platform
April 13,14, 2015 Paris (FR) DIA Europe
April 17, 2015 Brescia (I) Olimpiadi delle Neuroscienze
April 20, 2015 Rome (I): un Paese sano di mente?
April 22, 2015 2015 Rome (I) La Sanità in Italia: falsi miti e vere eccellenze
April 24, 2015 Rome (I) Fakeshare: international conference
May 4-5, 2015 London (UK) SAWP Meeting European Medicine Agency
May 9, 2015 Milan (I) Farmacista Più: il futuro della professione
May 9, 2015 Bologna (I) Festival della Medicina
May 12, 2015 Rome (I) Seminario La Scienza della buona ricerca clinica
May 15, 2015 Rome (I) Farmaci, dispositivi medici, prodotti naturali: efficacia e sicurezza al servizio
del paziente
May 22, 2015 Viterbo (I) Convegno: Evidence Based Medicine
June 3-4, 2014 London (UK) SAWP Meeting European Medicine Agency
June 6, 2015 Spoleto SpreK.O. 2015 – Seconda Festa nazionale per la lotta agli sprechi.Tavolo
Tecnico Il Sole 24 OreJune 10-11, 2015 London Management Board Meeting of EMA.
June 12, 2015 Rome Media tutorial "Concetti e linguaggi dell'Innovazione Farmacologica". Concetti e
linguaggi dell’innovazione farmacologica.
June 21-25, 2015 Miami (USA) ASCP Annual Meeting
June 30, 2015 Rome (I) Seminar Breakfast “Anticorruzione e Competitività”
July 2, 2015 Rome Assemblea Pubblica Farmindustria. Le Imprese del farmaco in Italia. Innovazione,
occupazione e produzione per un Paese in salute
July 2, 2015 Rome (I) CONVEGNO REGISTRI IMS. Evento Inwork Salute.
July 2, 2015 Rome (I) Obesity and Type 2 Diabetes Management: Fighting the Double Burden - 8th
Italian Barometer Diabetes Forum 3rd Diabetes experts panel meeting.
July 6-7, 2015 London (UK) SAWP Meeting European Medicine Agency
July 8-9, 2015 Luxembourg (LU) Heads of Medicines Agencies Meeting (HMA
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 25 / 27
Curriculum vitae
Luca Pani
July 10, 2015 Rome (I) Tavolo Economist. Value-BAsed Healthcare in Italy - a high-level roundtable
discussion.
July 11-12, 2015 Rome (I) 3rd Annual MGH CTNI.
July 16, 2015 Rome Convegno “PAY-BACK = GO BACK?. Palazzo Montecitorio.
July 19, 2015 Elmas Festival della letteratura della Sardegna. Sulla terra leggeri.
August 25, 2015 Cupertino (USA) A Federated Approach to Designing Devices for Dementia.
September 2-3, 2015 London (UK) SAWP Meeting European Medicine Agency
September 23, 2015 Rome (I) Le nuove sfide in retinologia: Appropriatezza e Sostenibilità delle Cure.
Camera dei Deputati.
October 1-2, 2015 London (UK) Management Board Meeting of EMA
October 5-7, 2015 London (UK) SAWP Meeting European Medicine Agency
October 8-11, 2015 Boca Raton (USA) CNS Summit 2015
October 15, 2015 Rome (I) Giornata di Studio AFI “La documentazione di Qualità, Sicurezza ed
Efficacia dei prodotti di origine vegetale: integratori e medicinali vegetali"
October 21-23, 2015 Dubrovnik (CR) Heads of Medicines Agencies Meeting (HMA)
November 3-4, 2015 London (UK) SAWP Meeting European Medicine Agency
November 16, 2015 Rome (I) 25° Congresso Nazionale SIUMB
November 18, 2015 Brussels (B) Professional Public Affairs (FIPRA)
November 24, 2015 London (UK) EU Telematics Management Board (EUTMB)
November 26-28, 2015 Florence (I) 32° Congresso Nazionale SIMG
November 30-1 December, 2015 London (UK) SAWP Meeting European Medicine Agency
December 3, 2015 Rome (I) Il Forum delle Neuroscienze
December 5, 2015 Milan (I) Corso di aggiornamento in nefrologia e metodiche dialitiche
January 12-13, 2016 London (UK) SAWP Meeting European Medicine Agency
January 15, 2016 Rome (I) Accesso ai farmaci, un diritto umano
January 21, 2016 Rome (I) La ricerca clinica parla europeo, la nuova sfida per istituzioni ed imprese
January 26, 2016 Rome (I) La depressione: stato dell’arte 2016
February 2, 2016 London (UK) Annual meeting of the EU TMB and industry
February 8, 2016 London (UK) SAWP Meeting European Medicine Agency
February 16, 2016 Amsterdam (NL) AESGP Conference with the EU Heads of Medicines Agencies
(HMA)
February 17-18, 2016 Amsterdam (NL) Heads of Medicines Agency (HMA)
February 19, 2016 Milan (I) 1st WAidid Congress
February 22-23, 2016 New York (USA) "Influence, Relevance, Growth Italy’s opportunity and new
paradigm"
March 1,2016 London (UK) The Economist's Value-based Healthcare in Europe summit
March 3-4, 2016 Washington (USA) IOM Workshop on Neuroscience Trials of the Future
March 9, 2016 Rome (I) Seminario Crusoe-Cerm sulla nuova governance farmaceutica.
March 14, 2016 Milano ( I ) Lezioni sul Progresso promosse dalla Fondazione Telecom Italia
March 15-16, 2016 London (UK) SAWP Meeting European Medicine Agency
March 18-19, 2016 Firenze ( I ) Congresso FarmacistaPiù
March 21-22, 2016 Firenze ( I ) International S&T Foresight Group - National Research Council of Italy
April 6-8, 2016 Hamburg (DE) DIA 28th Annual Euromeeting
April 11-12, 2016 London (UK) SAWP Meeting European Medicine Agency
April 13, 2016 Milan (I) Farmaci innovativi e sostenibilità del sistema sanitario nazionale.
Il superamento del tetto della spesa ospedaliera e territoriale:
il percorso verso la nuova governance
April 14, 2016 Bologna (I) Filiera del Farmaco 4.0 - Il Network dell’Innovazione nella Sanità Digitale
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 26 / 27
Curriculum vitae
Luca Pani
April 14, 2016 Bologna (I) L’ Anziano e l’Assistenza Farmaceutica
April 18, 2016 Amsterdam (NL) Riunione Informale dei Ministri della Salute dell'UE
Other Relevant Information
Mother tongue(s) Italian
Other language(s)
ENGLISH Proficient User
FRENCH Basic User
SPANISH Basic User
Organisational / managerial skills
During the last couple of years Luca Pani has supervised and followed to conclusion several project
and research grants both at regional, national and international level.
All major molecular biology techniques with particular respect to gene expression;
General Pharmacology; Brain Microdyalisis;
Advanced Clinical Skills in Psychiatry
Computer skills
Advanced Knowledge of PC and Mac main Programs;
Founder and Scientific Technical Supervisor of several Website see for example:
www.medol.com (One of the first www site with links to controlled medical information)
www.brainlab.it (A sponsor based site with the largest psychiatric on-line community in Italy)
www.case-builder.com (The first global company that is enterly based on educational interactive
algotithms)
Other skills
Radio Series:
Astolfo Sulla Terra,
Fantasy Fairy Tales Series (with GM De Muro and S Carta)
RAI, Italian National Broadcast Network, 1978-1979
Books:
Pani L.
Le Carte di Ephedra.
Kalb Editore, Cagliari, Italy 2007 (168 pp.)
Tennis Player, Amateur Ranking
Driving licence
Italian Driver Licence type A and B;
Held for several year Driver Licence in California, Illinois and Washington D.C.; Florida (current # DL
PXXXXXXXXX60);
Nautical Licence Sail and Power (unlimited from the coast);
Licence to operate a radiotelegraph on vessels.
7/11/16
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 27 / 27